Welcome to our dedicated page for Scynexis SEC filings (Ticker: SCYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SCYNEXIS, Inc. (SCYX) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on SCYNEXIS’s antifungal drug development programs, its exclusive license agreement with GSK for ibrexafungerp and BREXAFEMME, financial condition, governance, and risk factors.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for comprehensive discussions of the company’s fungerp platform, including ibrexafungerp and second-generation candidate SCY-247, as well as descriptions of clinical programs, collaboration terms, and revenue recognition from the GSK license agreement. These periodic reports also summarize research and development expenses, selling, general and administrative costs, cash balances, and other key financial metrics.
Current reports on Form 8-K capture material events such as the binding memorandum of understanding with GSK resolving the disagreement over the Phase 3 MARIO study, associated payments, and updates on the transfer of the BREXAFEMME New Drug Application. Other 8-K filings describe Nasdaq listing notices, annual meeting voting results, and similar corporate developments.
This page also surfaces proxy statements and related materials that address director elections, advisory votes on executive compensation, and auditor ratification. Together, these documents help users understand SCYNEXIS’s governance structure and shareholder decisions.
Stock Titan enhances these filings with AI-powered summaries that explain complex sections in plain language, highlight key changes from prior periods, and point out items such as license agreement terms, clinical program disclosures, and capital structure details. Users can quickly scan new 10-K, 10-Q, and 8-K filings, as well as track warrant liabilities, deferred revenue, and other line items that SCYNEXIS reports in its financial statements.
SCYNEXIS INC Chief Executive Officer David Angulo Gonzalez purchased additional equity through a private placement. On March 30, 2026, he agreed to buy 108,695 shares of common stock and accompanying warrants to purchase up to 108,695 shares, which closed on April 1, 2026, at a combined purchase price of $0.92 per share and warrant unit. The new Common Warrants will become exercisable once stockholders approve an increase in authorized common shares and will expire on the earlier of five years from issuance or 30 days after SCYNEXIS releases Week 48 topline data from its Phase 2 proof-of-concept clinical study of SCY-770 in autosomal dominant polycystic kidney disease. Following these transactions, he directly owns 1,357,126 shares of common stock, including 4,000 acquired under the 2014 Employee Stock Purchase Plan.
SCYNEXIS, Inc. outlines a new rare-disease strategy built around SCY-770, a Phase 2–ready oral AMP-activated protein kinase activator for autosomal dominant polycystic kidney disease (ADPKD). The company acquired global rights to SCY-770 from Poxel with $8M upfront, up to $8M in development milestones, and up to $180M in commercial milestones, with no royalties.
SCYNEXIS reports a stronger balance sheet, highlighting approximately $56M in cash, cash equivalents and investments as of December 31, 2025 and about $40M of gross proceeds from a recent PIPE financing, extending its cash runway into mid-2029. Management plans to start a Phase 2 proof-of-concept study in ADPKD in Q4 2026, targeting an early efficacy readout in the second half of 2027, while continuing to advance antifungal candidate SCY-247 and royalty-bearing asset BREXAFEMME.
SCYNEXIS, Inc. entered into a private placement with institutional and accredited investors to raise approximately $40.0 million in gross proceeds. The company will issue 34,750,000 common shares, 8,750,000 pre-funded warrants, and accompanying common warrants to purchase up to 43,500,000 shares or pre-funded warrants.
Common shares plus warrants are priced at $0.92 per unit, and pre-funded warrant units at $0.9199. Common warrants carry a $1.20 exercise price and become exercisable after stockholder approval of an authorized share increase. If all warrants are exercised for cash, SCYNEXIS could receive up to an additional $52.2 million.
The company plans to use net proceeds for working capital and general corporate purposes. It estimates that existing cash, cash equivalents and marketable securities, together with anticipated net proceeds from this financing, will fund operations into mid‑2029, supporting development of programs including SCY‑770 for autosomal dominant polycystic kidney disease.
SCYNEXIS, Inc. entered into an Asset Purchase Agreement with Poxel SA to acquire Poxel’s direct AMP kinase activator research program, including lead compound PXL-770, now SCY-770, for rare kidney disease ADPKD. SCYNEXIS will make a one-time upfront payment of $8,000,000 within 30 days of the agreement’s effective date and may pay up to $188,000,000 in development and commercial milestone payments tied to clinical progress and annual net sales thresholds.
The deal also includes an exclusive, sublicensable, perpetual worldwide license to related Poxel intellectual property. SCY-770 has been tested in eight clinical trials with a favorable safety profile and is planned to enter a Phase 2 proof-of-concept study in ADPKD in Q4 2026, with an early efficacy readout anticipated in the second half of 2027. SCY-770 holds FDA Orphan Drug Designation, while SCYNEXIS continues to develop its antifungal franchise, including potential BREXAFEMME milestones up to $146 million and ongoing Phase 1 work on SCY-247.
SCYNEXIS, Inc. focuses on severe fungal infections, built around its novel "fungerp" antifungal platform. Its first drug, ibrexafungerp (BREXAFEMME), is licensed globally to GSK for vulvovaginal candidiasis and recurrent VVC.
The lead wholly owned asset, SCY-247, completed single and multiple ascending dose Phase 1 oral studies in 88 healthy subjects, showing good tolerability and generally dose‑proportional pharmacokinetics. An intravenous Phase 1 trial began in early 2026, with a Phase 2 invasive candidiasis study planned for 2026.
Under a GSK license, SCYNEXIS ran the MARIO Phase 3 ibrexafungerp study, then agreed in an October 2025 memorandum to wind it down, receiving one‑time payments totaling $24.8 million in addition to a $10.0 million development milestone earlier in 2025.
SCYNEXIS reported an accumulated deficit of about $385.1 million and cash, cash equivalents and investments of $56.3 million as of December 31, 2025. The company expects continuing operating losses and will require substantial additional capital while it advances SCY‑247 and evaluates further partnering and in‑licensing opportunities.
Avidity Partners and affiliates reported a significant passive stake in Scynexis, Inc. common stock on Schedule 13G/A (Amendment No. 8). The group, including Avidity Partners Management LP and Michael Gregory, is shown as beneficially owning 4,426,565 shares, representing 9.9% of Scynexis’s common stock as of the event date.
The holdings are largely split between Avidity Master Fund LP with 852,750 shares (2.0% of the class) and Avidity Private Master Fund I LP with 3,573,815 shares (8.1% of the class), over which the reporting persons share voting and dispositive power. They certify the securities were not acquired to change or influence control of Scynexis.
SCYNEXIS, Inc. received an amended Schedule 13G/A from Kingdon Capital Management, L.L.C. and Mark Kingdon reporting that they now beneficially own 0 shares of the company’s common stock, or 0% of the class, as of December 31, 2025.
They report no sole or shared voting or dispositive power over any SCYNEXIS shares and indicate ownership of 5 percent or less of the class. They also certify that any securities previously held were not acquired to change or influence control of the company.
SCYNEXIS Inc. reported an equity award to its Chief Financial Officer. On 01/29/2026, CFO Macleod Ivor received 129,833 shares of common stock at a price of $0, reported as an acquisition.
These shares represent restricted stock units that vest in three equal annual installments starting February 28, 2026. Following this grant, the officer beneficially owns 398,529 shares directly.
SCYNEXIS Inc. granted equity compensation to its Chief Legal Officer, Scott Sukenick. On January 29, 2026, he received 129,833 shares of common stock at a price of $0 per share in the form of restricted stock units. These units vest one third per year over three years starting February 28, 2026, providing time-based retention incentives. Following this grant, he beneficially owns 574,539 shares of SCYNEXIS common stock in direct ownership.
SCYNEXIS Inc. reported an equity award to its CEO, David Angulo Gonzalez. On January 29, 2026, he received 391,333 shares of common stock as a stock-based grant priced at $0 per share, structured as restricted stock units.
After this award, he beneficially owned 1,244,431 shares of SCYNEXIS common stock in total. The restricted stock units vest in three equal annual installments, with vesting measured from February 28, 2026, which ties the award to multi‑year service and performance with the company.